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Abstract 
Introduction: In attempting to improve local tumor control by higher doses of radiation, there has been a resurgence of interest in the 
implementation of brachytherapy in the management of primary and recurrent cancers of the nasopharynx. Brachytherapy with its steep 
dose fall-off is of particular interest because of the proximity of critical dose limiting structures. Recent developments in brachytherapy, 
such as the introduction of pulsed-dose-rate and high-dose-rate computerized afterloaders, have encouraged further evolution of brachyther- 
apy techniques. 
Materials and methods: We have dcsigncd an inexpensive, reusable and flexible silicone applicator, tailored to the shape of the soft 
tissues of the nasophaqmx, which can be used with either low-dose-rate brachytherapy or high (pulsed)-dose-rate remote controlled 
afterloaders. 
Results and conclusions: This Rotterdam nasopharynx applicator proved to be easy to introduce, patient friendly and can remain in situ 
for the duration of the treatment (2-6 days). The design, technique of application and the first consecutive 5 years of clinical experience in 
using this applicator are presented. 0 1997 Elsevier Science Ireland Ltd. 
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1. Introduction 
In cancer of the nasopharynx (NP), stage III-IV disease 
predominates, comprising approximately 75% of patients. 
The most important single prognostic factor is the extent of 
the primary lesion at the time of presentation [II]. Naso- 
pharyngeal cancer (NPC) is known to be highly responsive 
to RT. Since NPC is also associated with a relatively high 
incidence of systemic recurrences, some reports advocate 
the combination of RT and chemotherapy (CHT) for the 
locally advanced cases [I]. Despite this, a local relapse 
still represents the most common type of failure, i.e. 
* Corresponding author. Daniel den Hoed Cancer Center, Groene Hille- 
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depending on stage, local recurrence rates range from 30 
to 60% [7,8,13]. Evidence suggests that the propensity for a 
local failure relates in particular to the locally applied dose 
[2,12,13,16]. However, the application of high doses of RT 
is not without considerable potential morbidity. In recent 
years there has been a resurgence of interest in the imple- 
mentation of brachytherapy (BT) in the management of 
primary or recurrent cancers of the NP [4,14,15,17]. To 
boost the NP with high doses of radiation, BT, with its 
rapid dose fall-off, is of particular interest because of the 
proximity of critical dose limiting (neural) structures. In an 
attempt to treat this secluded anatomical midline structure 
by BT, the ingenuity of clinical researchers is exemplified 
by the numerous endeavors to improve on the technique [5]. 
Moreover, recent developments in BT, such as pulsed-dose- 
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rate and high-dose-rate computerized afterloaders, using 3D 
computer planning systems with optimization capabilities, 
have even further encouraged the evolution of (endocavi- 
tary) BT afterloading techniques [9]. The purpose of this 
report is to describe the design of a new, flexible nasophar- 
yngeal applicator, tailored to the configuration of the soft 
tissues of the NP, to be used in combination with high-dose- 
rate (HDR) remote controlled afterloading systems. The 
Rotterdam nasopharynx applicator (RNA) was designed to 
be patient friendly and therefore easy to introduce as an 
outpatient procedure and to remain in situ for the duration 
of the treatment (2-6 days). 
2. Materials and methods 
2.1. NPC treatment protocol 
With the introduction in the Department of Radiation 
Oncology of a remote controlled ,HDR afterloader (Micro- 
Selectron HDR, Nucletron-Oldelft), HDR-BT was routinely 
implemented as a boost after ERT. Since 1991, for primary 
Tl-3 squamous cell carcinoma (SCC) of the NP without 
parapharyngeal extension, 60 Gy is applied by ERT using 
conventional fractionation (2 Gy per fraction/5 days per 
week) [6]. After a rest period of l-2 weeks, a booster 
dose is given to the primary tumor site by BT, using 3 Gy 
per fraction, two fractions per day with a 6 h interval in- 
between the fractions for six fractions in total (total dose 
(TD) 18 Gy, cumulative dose NP 78 Gy). In the case of 
primary cancers with parapharyngeal extension or T4 
tumors, 70 Gy is applied by ERT, followed by four fractions 
of 3 Gy (two fractions per day, 6 h interval) by HDR-BT 
(TD 12 Gy, cumulative dose NP 82 Gy). Lymphnodal dis- 
ease in the neck is treated with a cumulative dose of 70 Gy. 
In the case of a recurrent cancer, fractionated HDR-BT only 
is the preferred treatment mode, with cumulative doses tai- 
lored to the individual clinical situation. 
2.2. Design of RNA - a stereolithography model study 
Preferably, the introduction of the RNA and the applica- 
tion of the HDR-BT are performed on an outpatient basis. 
Given the total number of fractions (4-6), for patient con- 
venience the RNA was designed such that the application 
needs to be performed only once. The applicator was there- 
fore made out of silicone (type 625, Wacker Chemie, Krom- 
menie, The Netherlands) (flexibility) and remains in situ for 
the duration of the treatment which varies from 2 to 6 days 
depending on whether a weekend (no RT given) is included 
in the total treatment duration (Fig. 1). The inner diameter of 
the silicone tubing (o.d. 15 french, i.d. 9 french) can accom- 
modate standard afterloading catheters (o.d. 6 french). The 
shape of the silicone applicator (tubing) should ideally clo- 
sely conform to the nasopharyngeal vault. If so, the radio- 
active source can be positioned closer to the base of the 
skull (BOS) as opposed to the soft palate. Computer tomo- 
graphic scan data (Siemens Somaton Plus) (3 mm slices) 
were obtained from two NPC patients (Caucasian, Indone- 
sian) with a complete remission after ERT. From these CT 
slices, a stereolithographic machine (Materialise NV, 
Heverlee, Belgium) was able to reproduce a solid anatomi- 
cal model by lighting successive thin layers of a photopo- 
lymer with a computer controlled laser beam. In this case, 
the threshold of the machine was set such that the model 
represented the anatomy of the soft tissues. The stereolitho- 
graphic model was then sagitally sliced in a way which 
made it possible to study the confinements of the air cavities 
of the nose and the NP proper. Silicone tubing was posi- 
tioned in the nose and NP; a silicone flange was constructed 
in order to fixate the curvature of the tubing at the site of the 
NP proper and/or to push the applicator tubing towards the 
NP mucosa, i.e. away from the soft palate. Both tubes were 
interconnected by a small silicone (perforated) bridge (Fig. 
1) which abuts proximally to the nasal septum. No differ- 
ence was observed between the two patients with regard to 
the shape of the RNA. After decongestion (RKylometazo- 
line HCl 1%) and topical anesthesia, the RNA can be easily 
introduced into the NP transorally over 4 french (o.d.) guide 
tubes [lo]. Finally, by a small silicone flange (Fig. 1) the 
RNA remains fixed in a stable position for the treatment 
period. The silicone RNA can be re-used after cleansing 
and sterilizing with steam (120°C). 
2.3. Dose prescription and optimization 
After insertion of standard afterloading catheters with 
dummy sources into the RNA (Fig. 2), treatment planning 
is based on orthogonal radiographs. Patient points represent- 
ing the target (T), i.e. Na, R and BOS, as well as the critical 
normal tissues (NT), i.e. OC, P, Re, Pa and C, are depicted 
on lateral and anterior-posterior simulation films according 
to a well defined departmental protocol (for definition of 
position patient points see legend to Fig. 2). The obtained 
dose distribution is optimized such that Na (and if possible 
R) receives a dose of 3 Gy (reference dose) and the NT 
Fig. 1. Standard silicone Rotterdam nasophaqmx applicator (RNA). 
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Fig. 2. Lateral (Lat) and anterior-posterior (AP) X-ray simulation films of an NPC patient with RNA (dummy sources inclusive) in situ. After placing lead 
markers on the (contralateral) outer canthus (1) and tragus (2), a reference line is drawn from (1) to (2); 1 cm posterior from (l), a normal tissue point for the 
retina (Re) is depicted. A second reference line is drawn between the anterior clinoid process (3) and the position of the node of Rouviere (R) (ventral part 
corpus C-I). The pituitary gland (P) is positioned 0.5 cm from (3) (center of sella) on the second reference line; the intersection of line (3-R) with the first 
reference line (l-2) represents the base of the skull target point (BOS). The optic chiasm (OC) is located on the skull base, 1.5 cm ventrally from (3). At the 
junction of the hard and soft palate, a normal tissue point (Pa) is indicated. The intersection of the Pa-BOS line with the bony outline of the base of the skull is 
taken as the target point for prescribing the dose to the nasopharynx (Na). Directly posterior to R, at the posterior border of corpus C-I, a normal tissue point 
for the cord (C) is indicated. The OC, P, C and R points are single midline patient points. BOS, Re, Na and Pa are bilateral patient points at 1.5,2.5, 1.5 and 1 
cm from the midline, respectively. The stipulated line on the lateral and AP X-ray films represents the 3 Gy (reference) isodose line. 
points receive a dose as low as reasonably achievable in 
terms of the tolerance constraints (Table 1). This is done 
by assigning different weighting factors to each patient 
point. After treatment planning, afterloading catheters are 
introduced into the RNA with each fraction and connected 
to an HDR afterloading device with a high activity (370 
GBq) Iri9* stepping point source. Prom 1991 to 1995, 41 
consecutive primary NPC patients were treated with ERT 
and HDR-BT, according to the Rotterdam NPC protocol, 
testing the efficacy of the RNA applicator. Out of the 41 
cases, three patients presented with Tl (7%), nine patients 
presented with T2 (22%), 17 patients presented with T3 
(42%) and 12 patients presented with T4 (29%) tumor 
stages. Thirty-three patients (81%) were diagnosed with 
lymph nodes in the neck. 
3. Results and discussion 
Some literature data are strongly suggestive of the exis- 
tence of a dose-response relationship in NPC [2,3,12, 
13,16,17]. Therefore, in order to escalate doses and at the 
same time circumvent potential problems of surpassing the 
tolerance levels of neighboring critical structures, a combi- 
nation of ERT (primary tumor and bilateral neck) and BT 
(for boosting the primary site) seems advantageous. As BT 
for cancers in the head and neck in our center is given in 
general by fractionated HDR schedules [9], this created the 
need for an applicator with a novel design, in particular 
suitable to remain in situ for the duration of the fractionated 
BT treatment and to be used in conjunction with an HDR 
afterloader. After testing the RNA for 5 consecutive years, 
we feel it is safe to conclude that this flexible (silicone) and 
re-usable applicator is easy to introduce and can remain in 
the patient for the usual number of treatment days (2-6 
days), with only minimal discomfort, i.e. three patients 
developed synechie of part of the posterior nasal mucosal 
linings. This can easily be prevented by adequate packing of 
the nose for approximately 1 week post-BT. Obviously, the 
RNA could also be loaded with other types of (low activity) 
Table 1 
Example of brachytherapy dose distribution, non-optimized and opti- 
mized, in target and normal tissue patient points for a single patient treated 
by HDR endocavitary brachytherapy 
Patient points 
NA CR) 
NA 6) 
BOS (R) 
BOS (L) 
R 
oc 
P 
Re (RI 
Re (L) 
Pa CR) 
Pa CL) 
C 
Non-optimized dose 
(cGY) (%) 
268 (89) 
332 (111) 
146 (49) 
128 (43) 
366 (122) 
45 (15) 
69 (23) 
48 (16) 
60 (20) 
213 (71) 
253 (84) 
90 (30) 
Optimized dose 
(cGY) WJ) 
292 (97) 
308 (103) 
146 (49) 
128 (43) 
303 (101) 
46 (15) 
70 (23) 
52 (17) 
61 (20) 
238 (79) 
248 (83) 
78 (26) 
The obtained dose distribution is optimized such that the Na and R points 
receive (approximately) the reference dose of 3 Gy and the NT points 
receive a dose as low as can reasonably be achieved. This is done by 
assigning, by trial and error, different weighting factors for dose require- 
ments to each patient point. L, left; R, right. For an explanation of patient 
points, see legend to Fig. 2. 
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Fig. 3. Local relapse free survival for primary NPC patients treated from 
1991 to 1995 in Rotterdam by a combination of ERT and HDR-BT. 
radioactive sources, once the outer diameter of the source 
fits into the standard afterloading catheters. 
Since the cumulative doses used were substantial (T3, 78 
Gy; T4, 82 Gy), from the start it was felt mandatory to 
devise a scheme with a number of reproducible patient 
points, not only in order to optimize the dose to fixed anat- 
omy-based tumor points, but also to try and keep the doses 
in the critical normal tissues as low as reasonably feasible. 
For 40 patients we were able to estimate in retrospect (by 
point dose calculations) the cumulative doses that had been 
applied by ERT and BT. From the computed median doses 
(and the dose ranges) for all patient points (data not shown), 
it was concluded that this type of optimized BT apparently 
does not lead to overdosing of the critical normal structures. 
Finally, in this small consecutive series of 41 patients 
treated prospectively with a rigidly adhered to HDR-BT 
protocol, the local relapse free survival (LRFS) of Tl-3 
(n = 29) cancers at 5 years was 96% versus 57% for T4 
(n = 12) tumors (P = 0.002) (Fig. 3). Similar findings 
have been reported by others [3,17]; e.g. for Tl-3 tumors 
treated by ERT combined with low-dose-rate BT at 5 years 
an LRFS of 91% was found versus 60% for those treated by 
ERT only [17]. Apparently, it seems that BT might play a 
particularly important role in Tl-3 cancers. At present, we 
are in the process of performing a formal multivariate ana- 
lysis for all NPC patients treated between 1965 and 1995 in 
our cancer center. In that report we will specifically address 
the clinical impact of BT. 
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